Saxena, Gauri K.
Theocharopoulos, Ioannis
Aziz, Nisha Thaslima
Jones, Meleri
Gnanapavan, Sharmilee
Giovannoni, Gavin
Schmierer, Klaus
Garnett, James A.
Baker, David
Kang, Angray S. http://orcid.org/0000-0002-4672-4114
Article History
Received: 19 September 2019
Accepted: 26 December 2019
First Online: 5 February 2020
Competing interests
: AK has trademarked GloBody and filed patents for potential commercial development related to the GloBody ADA technology. GG, SG, KS have received fees for consultancy, meetings and grant support (SG) from Sanofi Genzyme within the last three years, otherwise none are considered relevant. However, SG has received travel support, consultancy fees or grant support from Biogen, Novartis, Teva, Pfizer, and Takeda. DB has received consultancy and presentation fees from Canbex Therapeutics, Japan Tobacco, Merck and Roche. KS has consultancy and presentation fees from Biogen, Bayer HealthCare, Lipomed, Medday, Merck, Novartis, Roche and Teva. GG has received consultancy, presentation fees or grants from AbbVie Biotherapeutics, Bayer Healthcare, Biogen, Canbex, Celgene, Ironwood, Japan Tobacco, Merck, Novartis, Roche, Sanofi-Genzyme, Synthon, Takeda, Teva and Vertex.